Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Z Potter

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Pharmaceutical Medicine|July 25, 2020
The NIMH 'Fast-Fail Trials' (FAST) Initiative: Rationale, Promise, and ProgressMargaret C Grabb, Mi Hillefors, William Z Potter
Biomarkers in Neuropsychiatry|August 25, 2021
BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSISJoshua B Ewen, William Z Potter, John A Sweeney
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 6, 2024
The origins of ADNIWilliam Z Potter, Neil S Buckholtz, Steven M Paul
Frontiers in Integrative Neuroscience|September 10, 2019
Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental DisabilitiesJoshua B Ewen, John A Sweeney, William Z Potter
Journal of Clinical Psychopharmacology|January 25, 2003
Dual monoamine modulation for improved treatment of major depressive disorderPierre V Tran, Frank P Bymaster, Robert K McNamara, et al.
Convulsive Therapy|January 1, 1988
Disparate Biochemical Actions of Electroconvulsive Therapy and Antidepressant DrugsMatthew V. Rudorfer, Emile D. Risby, John K. Hsiao, et al.
Journal of Clinical Psychopharmacology|June 23, 2004
Chronic lithium administration enhances noradrenergic responses to intravenous administration of the alpha2 antagonist idazoxan in healthy volunteersAyşegül Ozerdem, Mark E Schmidt, Husseini K Manji, et al.
Stress (Amsterdam, Netherlands)|September 18, 2003
LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stressDarryle D Schoepp, Rebecca A Wright, Louise R Levine, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 11, 2010
The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory BoardMark E Schmidt, Eric Siemers, Peter J Snyder, et al.
Drug and Alcohol Dependence|March 26, 2018
Novel prodrug PRX-P4-003, selectively activated by gut enzymes, may reduce the risk of iatrogenic addiction and abuseSandeep T Patil, Ron H Bihovsky, Steven A Smith, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Pharmaceutical Medicine|July 25, 2020
The NIMH 'Fast-Fail Trials' (FAST) Initiative: Rationale, Promise, and ProgressMargaret C Grabb, Mi Hillefors, William Z Potter
Biomarkers in Neuropsychiatry|August 25, 2021
BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSISJoshua B Ewen, William Z Potter, John A Sweeney
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 6, 2024
The origins of ADNIWilliam Z Potter, Neil S Buckholtz, Steven M Paul
Frontiers in Integrative Neuroscience|September 10, 2019
Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental DisabilitiesJoshua B Ewen, John A Sweeney, William Z Potter
Journal of Clinical Psychopharmacology|January 25, 2003
Dual monoamine modulation for improved treatment of major depressive disorderPierre V Tran, Frank P Bymaster, Robert K McNamara, et al.
Convulsive Therapy|January 1, 1988
Disparate Biochemical Actions of Electroconvulsive Therapy and Antidepressant DrugsMatthew V. Rudorfer, Emile D. Risby, John K. Hsiao, et al.
Journal of Clinical Psychopharmacology|June 23, 2004
Chronic lithium administration enhances noradrenergic responses to intravenous administration of the alpha2 antagonist idazoxan in healthy volunteersAyşegül Ozerdem, Mark E Schmidt, Husseini K Manji, et al.
Stress (Amsterdam, Netherlands)|September 18, 2003
LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stressDarryle D Schoepp, Rebecca A Wright, Louise R Levine, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 11, 2010
The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory BoardMark E Schmidt, Eric Siemers, Peter J Snyder, et al.
Drug and Alcohol Dependence|March 26, 2018
Novel prodrug PRX-P4-003, selectively activated by gut enzymes, may reduce the risk of iatrogenic addiction and abuseSandeep T Patil, Ron H Bihovsky, Steven A Smith, et al.
Pageof 7